In summary, these studies suggest that genetic or pharmacological inhibition of these pro-inflammatory mediators (iNOS, IL-6, CCL2, and CCL9) provides neuroprotection against stroke, which can affect pro-inflammatory mediators by modulating LCN-2. This evidence concerns the gene IL6 and stroke disorder.